[go: up one dir, main page]

WO1998020864A3 - Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives - Google Patents

Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives Download PDF

Info

Publication number
WO1998020864A3
WO1998020864A3 PCT/EP1997/006323 EP9706323W WO9820864A3 WO 1998020864 A3 WO1998020864 A3 WO 1998020864A3 EP 9706323 W EP9706323 W EP 9706323W WO 9820864 A3 WO9820864 A3 WO 9820864A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
treatment
neurodegenerative diseases
steroidal antiinflammatory
selected non
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/006323
Other languages
English (en)
Other versions
WO1998020864A9 (fr
WO1998020864A2 (fr
Inventor
Mariagrazia Grilli
Marina Pizzi
Maurizio Memo
Pierfranco Spano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Brescia
Original Assignee
Universita degli Studi di Brescia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Brescia filed Critical Universita degli Studi di Brescia
Publication of WO1998020864A2 publication Critical patent/WO1998020864A2/fr
Publication of WO1998020864A9 publication Critical patent/WO1998020864A9/fr
Publication of WO1998020864A3 publication Critical patent/WO1998020864A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne l'utilisation de composés anti-inflammatoires non stéroïdiens pour la prévention et le traitement de maladies neurodégénératives, telles que la maladie d'Alzheimer ou la maladie de Parkinson.
PCT/EP1997/006323 1996-11-13 1997-11-13 Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives Ceased WO1998020864A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI96A002356 1996-11-13
IT96MI002356A ITMI962356A1 (it) 1996-11-13 1996-11-13 Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di

Publications (3)

Publication Number Publication Date
WO1998020864A2 WO1998020864A2 (fr) 1998-05-22
WO1998020864A9 WO1998020864A9 (fr) 1998-08-27
WO1998020864A3 true WO1998020864A3 (fr) 1998-10-15

Family

ID=11375202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/006323 Ceased WO1998020864A2 (fr) 1996-11-13 1997-11-13 Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives

Country Status (2)

Country Link
IT (1) ITMI962356A1 (fr)
WO (1) WO1998020864A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255347B1 (en) 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
EP1100504A2 (fr) 1998-07-02 2001-05-23 Eisai Co., Ltd. Compositions pharmaceutiques et leur utilisation
IT1302898B1 (it) * 1998-12-03 2000-10-10 Medosan Ricerca Srl Uso di amtolmetine guacil per la produzione di farmaci ad effettoantiinfiammatorio nelle infiammazioni intestinali.
CA2379052A1 (fr) * 1999-08-10 2001-02-15 Uab Research Foundation Procede de traitement de traumatismes cerebraux et medullaires et d'autres conditions neurogeniques par des anti-inflammatoires non steroidiens et des conotoxines a l'etat naturel
KR100417623B1 (ko) * 2000-03-28 2004-02-05 주식회사 뉴로테크 뇌질환 예방 및 치료용 조성물
ATE366569T1 (de) * 2000-07-20 2007-08-15 Lauras As Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
DE10103506A1 (de) * 2001-01-26 2002-08-14 Ingo S Neu Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose
CA2486302A1 (fr) * 2002-05-17 2003-11-27 Faust Pharmaceuticals Methodes de prevention et/ou de traitement de troubles neurologiques
EP1371366A1 (fr) * 2002-05-17 2003-12-17 Faust Pharmaceuticals Méthode de prévention et de traitement de troubles neurologiques
KR101118807B1 (ko) 2002-06-06 2012-04-12 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 Ｏ-치환 히드록시아릴 유도체
EA011707B1 (ru) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения нейродегенеративных заболеваний
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
CA2503075A1 (fr) * 2002-10-21 2004-04-29 Ramot At Tel-Aviv University Ltd. Derives d'acide n-phenylanthranilique et de 2-benzimidazolone en tant que modulateurs de l'activite des canaux potassiques et/ou des neurones corticaux
WO2005033059A1 (fr) * 2003-10-08 2005-04-14 Innovaprotean, S.L. Composes utiles pour le traitement de maladies associees a la formation de fibrilles amyloides
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
WO2005115405A1 (fr) 2004-04-28 2005-12-08 Molecules For Health, Inc. Methodes permettant de traiter ou de prevenir la restenose et d'autres troubles vasculaires proliferants
US9216966B2 (en) 2004-10-04 2015-12-22 John Manfredi Compounds for Alzheimer's disease
CN101068781B (zh) * 2004-10-04 2012-02-01 美瑞德生物工程公司 用于阿尔茨海默氏病的化合物
EP1886681A3 (fr) * 2004-10-07 2008-11-19 Sulfidris S.r.l. 5-(p-hydroxyphényl)-3H-1,2-dithiol-3-thione ester de valproate
AU2007234399A1 (en) * 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
EP2030615A3 (fr) * 2007-08-13 2009-12-02 ELFORD, Howard L. Inhibiteurs de la ribonucleotide reductase pour leur utilisation dans le traitement ou la prévention de maladies neuro-inflammatoires ou auto-immunes
EP2203411B1 (fr) 2007-09-20 2016-01-06 Ramot at Tel-Aviv University Ltd. Dérivés de l'acide n-phénylanthranilique et leurs utilisations
CN101932316A (zh) * 2007-12-21 2010-12-29 Paz医药发展有限公司 药物制剂及其制备和其在治疗疼痛相关的神经病中的应用
EP2291182A1 (fr) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Conjugués de salicylés utiles pour le traitement de troubles métaboliques
CN102816082B (zh) * 2010-01-29 2015-03-11 浙江大学 苯甲酰胺类衍生物及制备方法和应用
CN101817761B (zh) * 2010-01-29 2014-06-25 浙江大学 苯甲酸酯类衍生物及制备方法和应用
EP2950797B1 (fr) 2013-02-01 2019-09-11 Glialogix, Inc. Compositions et méthodes utilisables en vue du traitement de maladies neurodégénératives et autres
US20150086616A1 (en) * 2013-09-20 2015-03-26 Steven Lehrer Method for the prevention and treatment of alzheimer's disease
GB201416017D0 (en) * 2014-09-10 2014-10-22 New Royal Holloway & Bedford An Anticonvulsant Compound
US20170143681A1 (en) * 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
JP6962572B2 (ja) * 2016-03-18 2021-11-05 学校法人同志社 ２，４−ジアミノフェノール誘導体、及び、タウ及び／又はアミロイドβの凝集阻害剤
WO2022243507A1 (fr) * 2021-05-20 2022-11-24 Institut Du Cerveau Et De La Moelle Epiniere Tenoxicam pour le traitement de protéinopathies du système nerveux central

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024115A1 (fr) * 1991-04-23 1993-12-09 The University Of British Columbia Utilisation de substances pharmaceutiques contre la polyarthrite rhumatismale pour le traitement de la maladie d'alzheimer
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
WO1997044020A1 (fr) * 1996-05-21 1997-11-27 Angelini Ricerche S.P.A. Societa' Consortile Utilisation de derives du p-aminophenol pour la preparation de compositions pharmaceutiques utiles dans le traitement de maladies neuro-degeneratives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024115A1 (fr) * 1991-04-23 1993-12-09 The University Of British Columbia Utilisation de substances pharmaceutiques contre la polyarthrite rhumatismale pour le traitement de la maladie d'alzheimer
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
WO1997044020A1 (fr) * 1996-05-21 1997-11-27 Angelini Ricerche S.P.A. Societa' Consortile Utilisation de derives du p-aminophenol pour la preparation de compositions pharmaceutiques utiles dans le traitement de maladies neuro-degeneratives

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BREITNER J C S ET AL: "DELAYED ONSET OF ALZHEIMER'S DISEASE WITH NONSTEROIDAL ANTI.INFLAMMATORY AND HISTAMINE H2 BLOCKING DRUGS", NEUROBIOLOGY OF AGING, vol. 16, no. 4, 1995, pages 523 - 530, XP002041828 *
C.B. ANDERSON ET AL.: "DIFLUNISAL IN IDIOPATHIC PARKINSON'S DISEASE", NEUROLOGY, vol. 34, no. 3, 1984, pages 400, XP002062729 *
I.S. NEU: "BEHANDLUNG DER MULTIPLEN SKLEROSE MIT SULFASALAZIN", NERVENHEILKUNDE, vol. 13, no. 2, 1994, pages 97 - 98, XP002062728 *
J.C.S. BREITNER: "WHY ANTI-INFLAMMATORY DRUGS MAY BE A TREATMENT FOR ALZHEIMER'S DISEASE", NEUROTOXICOLOGY, vol. 17, no. 3-4, October 1996 (1996-10-01), pages 942, XP002062730 *
J.E.F. REYNOLDS: "MARTINDALE, THE EXTRA PHARMACOPOEIA", 1996, ROYAL PHARMACEUTICAL SOCIETY, LONDON, XP002062731 *
J.S. MEYER ET AL.: "RANDOMIZED CLINICAL TRIAL OF DAILY ASPIRIN THERAPY IN MULTI-INFARCT DEMENTIA", JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, vol. 37, no. 6, 1989, pages 549 - 555, XP002062726 *
M. GRILLI ET AL.: "NEUROPROTECTION BY ASPIRIN AND SODIUM SALICYLATE THROUGH BLOCKAGE OF NF-KAPPAB ACTIVATION", SCIENCE, vol. 274, 22 November 1996 (1996-11-22), pages 1383 - 1385, XP002062723 *
M.W. RIEPE ET AL.: "ACETYLSALICYLIC ACID INCREASES TOLERANCE AGAINST HYPOXIC AND CHEMICAL HYPOXIA", STROKE, vol. 28, no. 10, October 1997 (1997-10-01), pages 2006 - 2011, XP002062724 *
R.J. OKEN ET AL.: "ALZHEIMER DISEASE: ASPIRIN PROPHYLAXIS AND THERAPY", ALZHEIMER DISEASE AND ASSOCIATED DISORDERS, vol. 6, no. 1, 1992, pages 53 - 54, XP002062725 *
Y. FUJITA ET AL.: "EVALUATION OF A LOW DOSE ADMINISTRATION OF ASPIRIN, DIPYRIDAMOL AND STEROID.", PARAPLEGIA, vol. 23, no. 1, 1985, pages 56 - 57, XP002062727 *

Also Published As

Publication number Publication date
ITMI962356A1 (it) 1998-05-13
ITMI962356A0 (it) 1996-11-13
WO1998020864A2 (fr) 1998-05-22

Similar Documents

Publication Publication Date Title
WO1998020864A3 (fr) Utilisation de composes anti-inflammatoires non steroidiens selectionnes pour la prevention et le traitement de maladies neurodegeneratives
AU1402895A (en) Use of pla2 inhibitors as treatment for alzheimer&#39;s disease
WO2003047577A3 (fr) Compositions pharmaceutiques et utilisations associees
IL121170A0 (en) Compositions for the treatment of dermatological disorders
AU1407399A (en) Treatment for alzheimer&#39;s disease
AU2830097A (en) Therapeutic method for treatment of alzheimer&#39;s disease
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer&#39;s disease
ZA977310B (en) Transdermal propentofylline compositions for the treatment of Alzheimer&#39;s disease.
AU7556994A (en) Methods for the diagnosis of alzheimer&#39;s disease
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
AU3364499A (en) Method for delaying the onset of alzheimer&#39;s disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
CA2301706A1 (fr) Utilisation de phanquinone dans le traitement de la maladie d&#39;alzheimer
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer&#39;s disease
AU3596797A (en) Methods for the treatment of apolipoprotein e related diseases
AU1405899A (en) Treatment for alzheimer&#39;s disease
AU1831195A (en) Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AU4215499A (en) Treatment of neurodegenerative diseases
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
AU2003299101A1 (en) Compounds for the treatment of alzheimer&#39;s disease
AU5854799A (en) Novel treatment of neurodegenerative diseases
AU1002697A (en) Topical compositions for the treatment of skin disease
AU2002300055A1 (en) Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer&#39;s disease and dementias
AU2002350043A1 (en) Hydroxy substituted amides for the treatment of alzheimer&#39;s disease
AU2002320537A1 (en) Diaminediols for the treatment of alzheimer&#39;s disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGE 4/4, DRAWINGS, REPLACED BY A NEW PAGE 4/4

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase